Catalyst Pharmaceuticals (CPRX) Current Assets (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Current Assets came in at $940.4 million in Q1 2026, up 37.14% YoY from $685.7 million in Q1 2025, and up 5.19% on a QoQ basis from $894.0 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Current Assets (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 17 years of Current Assets data on file, last reported at $940.4 million in Q1 2026.
- Quarterly Current Assets rose 37.14% year-over-year to $940.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $940.4 million (up 37.14% YoY) and the FY2025 annual result came in at $894.0 million, up 43.36% from the prior year.
- Current Assets rose to $940.4 million in Q1 2026, from $894.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $940.4 million in Q1 2026 to a low of $192.0 million in Q3 2023.
- A 5-year average of $475.6 million and a median of $404.6 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets tumbled 31.63% — and 2024, when it jumped 184.33%.
- Tracing CPRX's Current Assets over 5 years: stood at $320.8 million in 2022, then sank by 31.63% to $219.3 million in 2023, then jumped by 184.33% to $623.6 million in 2024, then surged by 43.36% to $894.0 million in 2025, then climbed by 5.19% to $940.4 million in 2026.
- The last three Current Assets figures came in at $940.4 million (Q1 2026), $894.0 million (Q4 2025), and $852.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 940.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 940.39 Mn |
| Dec 31, 2025 | 894.03 Mn |
| Sep 30, 2025 | 852.45 Mn |
| Jun 30, 2025 | 758.74 Mn |
| Mar 31, 2025 | 685.72 Mn |
| Dec 31, 2024 | 623.61 Mn |
| Sep 30, 2024 | 539.00 Mn |
| Jun 30, 2024 | 474.43 Mn |
| Mar 31, 2024 | 404.60 Mn |
| Dec 31, 2023 | 219.33 Mn |
| Sep 30, 2023 | 192.02 Mn |
| Jun 30, 2023 | 240.97 Mn |
| Mar 31, 2023 | 198.91 Mn |
| Dec 31, 2022 | 320.81 Mn |
| Sep 30, 2022 | 276.31 Mn |
| Jun 30, 2022 | 242.56 Mn |
| Mar 31, 2022 | 221.19 Mn |
| Dec 31, 2021 | 210.11 Mn |
| Sep 30, 2021 | 192.80 Mn |
| Jun 30, 2021 | 176.31 Mn |